Q1 margin and cash-flow gains were strong, but Q2 EBITDA is expected to decline amid healthcare weakness [102][128][163].
| Quarter | Q1 FY26 |
|---|---|
| Call date | 2026-05-06 |
| Length | 45 minutes |
| EPS | $0.06 |
| Revenue | $479.6M |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q2 FY26 · Q4 FY25
All MATV earnings · Back to MATV overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.